medivir - Robuta Search

https://www.biospace.com/medivir-to-present-data-on-additive-efficacy-of-fostrox-in-triple-combination-with-anti-pd1-and-kinase-inhibitor-in-nonclinical-tumor-models-at-aacr Medivir to present data on additive efficacy of fostrox in triple combination with anti-PD1 and... Mar 17, 2023 - Medivir AB announces that data from the company's leading program fostroxacitabine bralpamide and its potential effect on hepatocellular carcinoma, will be... https://www.fiercebiotech.com/medivir-delays-pivotal-hdac-trial-as-fda-discussions-stall Medivir delays pivotal HDAC trial as FDA discussions stall | Fierce Biotech Jun 18, 2018 - A year ago, Medivir was riding high after reporting midstage data that encouraged it to press ahead with a pivotal trial of its medivir delays pivotal hdac trial https://www.biospace.com/medivir-ab-swedish-osteoporosis-drug-begins-trials-in-humans Medivir AB: Swedish Osteoporosis Drug Begins Trials in Humans - BioSpace medivir ab swedish osteoporosis drug begins https://www.prnewswire.com/news-releases/execution-of-the-annual-general-meetings-resolution-on-the-removal-of-share-class-in-medivir-ab-publ-301816218.html Execution of the annual general meeting's resolution on the removal of share class in Medivir AB... /PRNewswire/ -- The annual general meeting in Medivir AB (publ), held earlier today on 4 May 2023, resolved to adopt new articles of association, whereby the... https://www.prnewswire.com/news-releases/nomination-committee-of-medivir-appointed-301411198.html Nomination Committee of Medivir appointed /PRNewswire/ -- Medivir AB (Nasdaq Stockholm: MVIR) today announces that the nomination committee now has been appointed ahead of the Annual General Meeting... nomination committee medivir appointed https://www.biospace.com/medivir-2023-annual-report-published Medivir 2023 Annual Report published - BioSpace Apr 5, 2024 - Medivir AB announces that the Annual Report for 2023 now is available at the company's website. 2023 annual report medivir published https://www.medivir.se/ Medivir - Science working wonders medivir science working wonders https://www.prnewswire.com/news-releases/notice-of-annual-general-meeting-of-medivir-ab-publ-301516763.html Notice of Annual General Meeting of Medivir AB (publ) /PRNewswire/ -- The shareholders of Medivir AB (publ), reg. no. 556238-4361, with its registered office in Huddinge, Stockholm, are hereby summoned to the... annual general meeting medivir ab notice publ https://www.biospace.com/the-medivir-board-is-seeking-issue-authorizations-to-increase-the-company-s-funding-flexibility-and-calls-for-an-extraordinary-general-meeting The Medivir Board is Seeking Issue Authorizations to Increase the Company's Funding Flexibility and... Jan 2, 2018 - Medivir today announces a notice for an Extraordinary General Meeting, to be held on 26 January 2018, with a proposal for the Meeting to authorize the Board of... https://theorg.com/org/medivir-ab?person=magnus-christensen Medivir | The Org Medivir is a Swedish biotech company. It focuses its research on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical... medivir https://www.biospace.com/change-in-the-number-of-shares-and-votes-in-medivir-ab-publ Change in the number of shares and votes in Medivir AB (publ) - BioSpace May 31, 2023 - Medivir AB announces that the number of shares and votes in Medivir has changed during May 2023 as a result of the previously announced share issue of 970,500... in the https://www.mynewsdesk.com/se/medivir/videos/introduction-to-cold-sores-3257 Introduction to cold sores | Medivir AB Recurrent herpes labialis (cold sores) is a common infection that affects one-third of the population in the Western world resulting in around 600 million... cold sores introduction medivir ab https://www.biospace.com/medivir-ab-year-end-report-january-december-2023 Medivir AB - Year-End Report January - December 2023 - BioSpace Feb 15, 2024 - The clinical efficacy of fostrox in combination with Lenvima continues to improve with median time to progression having increased to over 6 months. year end report medivir ab december 2023 january https://www.home.saxo/cs-cz/markets/stocks/mvir-xome Medivir AB akcie | Saxo Bank Medivir AB develops drugs with a focus on cancer, where unmet medical needs are high. medivir ab akcie saxo bank